TrialBMC medicine2025

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.

Xue-Feng Kan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.